Global Food Giants Pivot Strategies as GLP-1 Drugs Reshape Demand

Global food and beverage companies are re-evaluating their product offerings as appetite-suppressing GLP-1 drugs gain traction among consumers. Major players such as PepsiCo and Coca-Cola are focusing on simpler ingredient lists and smaller packaging sizes in response to the rising demand for these weight-loss medications. The shift in strategy signals a significant change in consumer behavior, with nearly 20 percent of U.S. households now using GLP-1 drugs, according to a PwC analysis.

The trend has prompted more than three dozen companies outside the healthcare sector to mention GLP-1 drugs or weight loss during their earnings calls in 2024. This marks a considerable increase from just 14 such mentions a year ago and a mere five two years prior, based on data from LSEG. Estimates from EY-Parthenon indicate that dietary changes associated with GLP-1 drug use could lead to a loss of up to US$12 billion in snack sales over the next decade.

Adapting to New Consumer Preferences

As the use of GLP-1 drugs becomes more common, companies are adjusting their product lines to accommodate changing consumer preferences. Peter ter Kulve, CEO of Magnum Ice Cream, noted that users of GLP-1 medications are still indulging in treats but are displaying a “stark reduction of mindless munching and binge eating.” This shift has influenced Coca-Cola’s new CEO, who emphasized the need for faster innovation during his first analyst call, and Kraft Heinz announced a commitment of US$600 million this year to revitalize its Oscar Mayer brand.

Investment in capital expenditure is on the rise, with companies like General Mills expecting increases of up to 23 percent. PepsiCo is launching a new line called “Simply NKD,” aimed at reformulating snacks and rebranding existing products by eliminating artificial colors. The company also plans to test mini-meal options with its Sabra and Siete brands, as outlined by CEO Ramon Laguarta at the Consumer Analyst Group of New York (CAGNY) conference.

Market Shifts and Future Trends

The impact of GLP-1 drugs extends beyond consumer choices, as firms like Conagra Brands are investing in snacks that cater to health-conscious consumers. The company has reported rising demand for protein-rich, portion-controlled, and nutrient-dense foods, particularly among younger generations such as Gen Z and millennials. “There’s not anyone out there that’s not designing, putting R&D dollars against this trend,” stated Peter Mangan, managing director at Portage Point Partners.

Emerging businesses are also recognizing the potential in this market. For instance, Snap Kitchen, an Austin-based company, is expanding its menu to include higher fiber and lean protein options that promote satiety. CEO Mitchell Raisch remarked, “The GLP-1 opportunity has sharpened our focus and accelerated our pipeline.”

According to PwC’s analysis, GLP-1 users consume, on average, 40 percent fewer calories, with dessert consumption down by 84 percent and alcohol use decreasing by 33 percent. In contrast, fresh produce intake has surged by more than 70 percent. These changes have resulted in smaller grocery baskets, with family sizes seeing reductions of 4 percent to 6 percent, and single-person households experiencing declines of up to 9 percent.

As the influence of GLP-1 drugs continues to reshape consumer habits, the food industry is beginning to understand the broader implications of this physiological shift. Ali Furman, PwC’s U.S. consumer markets leader, noted, “We’re just starting to scratch the surface on the ripple effects of this type of physiological disruption.” The evolving landscape promises to bring significant changes to how food and beverage companies approach their product strategies and engage with health-conscious consumers.